PharmAust Limited (PAA.AX)
AUD 0.23
(6.98%)
AUD 0.23
(6.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -9.71 Million AUD | -486.25% |
| 2023 | -1.65 Million AUD | -60.79% |
| 2022 | -1.03 Million AUD | 40.85% |
| 2021 | -1.74 Million AUD | -23.68% |
| 2020 | -1.4 Million AUD | 20.24% |
| 2019 | -1.76 Million AUD | -21.81% |
| 2018 | -1.44 Million AUD | 31.06% |
| 2017 | -2.1 Million AUD | -667.67% |
| 2016 | -273.92 Thousand AUD | 91.88% |
| 2015 | -3.37 Million AUD | -51.0% |
| 2014 | -2.23 Million AUD | -515.43% |
| 2013 | -362.87 Thousand AUD | -176.81% |
| 2012 | 472.45 Thousand AUD | 1041.27% |
| 2011 | -50.19 Thousand AUD | 98.13% |
| 2010 | -2.68 Million AUD | -10.9% |
| 2009 | -2.42 Million AUD | -533.91% |
| 2008 | 558.69 Thousand AUD | -65.34% |
| 2007 | 1.61 Million AUD | 4185.18% |
| 2006 | 37.61 Thousand AUD | 107.59% |
| 2005 | -495.91 Thousand AUD | -243.47% |
| 2004 | -144.38 Thousand AUD | 25.1% |
| 2003 | -192.77 Thousand AUD | -40.71% |
| 2002 | -137 Thousand AUD | 87.12% |
| 2001 | -1.06 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -9.71 Million AUD | 0.0% |
| 2024 Q2 | -5.45 Million AUD | 0.0% |
| 2024 FY | -9.71 Million AUD | -486.25% |
| 2023 Q4 | -1.65 Million AUD | 0.0% |
| 2023 FY | -1.65 Million AUD | -60.79% |
| 2023 Q2 | -953.36 Thousand AUD | 0.0% |
| 2022 Q2 | -1.39 Million AUD | 0.0% |
| 2022 Q4 | -1.03 Million AUD | 0.0% |
| 2022 FY | -1.03 Million AUD | 40.85% |
| 2021 FY | -1.74 Million AUD | -23.68% |
| 2021 Q4 | -1.74 Million AUD | 0.0% |
| 2021 Q2 | -2.19 Million AUD | 0.0% |
| 2020 Q4 | -1.4 Million AUD | 0.0% |
| 2020 Q2 | -1.36 Million AUD | 0.0% |
| 2020 FY | -1.4 Million AUD | 20.24% |
| 2019 Q4 | -1.76 Million AUD | 0.0% |
| 2019 Q2 | -396.92 Thousand AUD | 0.0% |
| 2019 FY | -1.76 Million AUD | -21.81% |
| 2018 FY | -1.44 Million AUD | 31.06% |
| 2018 Q4 | -1.44 Million AUD | 0.0% |
| 2018 Q2 | -2.55 Million AUD | 0.0% |
| 2017 Q2 | -2.12 Million AUD | 0.0% |
| 2017 FY | -2.1 Million AUD | -667.67% |
| 2017 Q4 | -2.1 Million AUD | 0.0% |
| 2016 Q4 | -273.92 Thousand AUD | 0.0% |
| 2016 Q2 | -792.05 Thousand AUD | 0.0% |
| 2016 FY | -273.92 Thousand AUD | 91.88% |
| 2015 Q2 | -1.1 Million AUD | 0.0% |
| 2015 Q4 | -3.37 Million AUD | 0.0% |
| 2015 FY | -3.37 Million AUD | -51.0% |
| 2014 Q1 | -2.7 Million AUD | -644.68% |
| 2014 Q2 | -2.61 Million AUD | 3.22% |
| 2014 Q4 | -2.23 Million AUD | 0.0% |
| 2014 FY | -2.23 Million AUD | -515.43% |
| 2013 Q1 | -500.45 Thousand AUD | -205.93% |
| 2013 FY | -362.87 Thousand AUD | -176.81% |
| 2013 Q4 | -362.87 Thousand AUD | 0.0% |
| 2013 Q3 | -362.87 Thousand AUD | 27.49% |
| 2013 Q2 | -500.45 Thousand AUD | 0.0% |
| 2012 FY | 472.45 Thousand AUD | 1041.27% |
| 2012 Q4 | 472.45 Thousand AUD | 0.0% |
| 2011 Q4 | -50.19 Thousand AUD | 0.0% |
| 2011 FY | -50.19 Thousand AUD | 98.13% |
| 2010 Q4 | -2.68 Million AUD | 0.0% |
| 2010 FY | -2.68 Million AUD | -10.9% |
| 2009 Q4 | -2.42 Million AUD | 0.0% |
| 2009 FY | -2.42 Million AUD | -533.91% |
| 2008 FY | 558.69 Thousand AUD | -65.34% |
| 2008 Q4 | 558.69 Thousand AUD | 0.0% |
| 2007 Q4 | 1.28 Million AUD | 0.0% |
| 2007 FY | 1.61 Million AUD | 4185.18% |
| 2006 Q4 | 37.61 Thousand AUD | 0.0% |
| 2006 FY | 37.61 Thousand AUD | 107.59% |
| 2005 Q4 | -495.91 Thousand AUD | 0.0% |
| 2005 FY | -495.91 Thousand AUD | -243.47% |
| 2004 FY | -144.38 Thousand AUD | 25.1% |
| 2004 Q4 | -144.38 Thousand AUD | 0.0% |
| 2003 Q4 | -192.77 Thousand AUD | 0.0% |
| 2003 FY | -192.77 Thousand AUD | -40.71% |
| 2002 Q4 | 243.86 Thousand AUD | 0.0% |
| 2002 FY | -137 Thousand AUD | 87.12% |
| 2001 FY | -1.06 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 48.599% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -889.109% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 291.701% |
| Biome Australia Limited | -1.56 Million AUD | -521.581% |
| Patrys Limited | -2.24 Million AUD | -333.538% |
| Orthocell Limited | -19.92 Million AUD | 51.246% |
| Imugene Limited | -91.56 Million AUD | 89.391% |
| Noxopharm Limited | -2.31 Million AUD | -318.725% |
| PYC Therapeutics Limited | -65.76 Million AUD | 85.228% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -218.182% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 4.414% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -53.611% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -56.542% |
| CSL Limited | 15.76 Billion AUD | 100.062% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 23.598% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -1269.037% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 94.691% |
| Starpharma Holdings Limited | -19.83 Million AUD | 51.018% |
| Nanollose Limited | -96.22 Thousand AUD | -9995.203% |
| Memphasys Limited | 4.13 Million AUD | 334.903% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -61.228% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -96.081% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -432.691% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 87.751% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -684.402% |
| Race Oncology Limited | -17.18 Million AUD | 43.486% |
| Nyrada Inc. | -4.76 Million AUD | -103.677% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 90.818% |
| Dimerix Limited | -21.99 Million AUD | 55.828% |
| Immutep Limited | -122.18 Million AUD | 92.05% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 92.884% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 22.162% |
| BTC Health Limited | -2.02 Million AUD | -380.384% |
| Acrux Limited | -1.45 Million AUD | -566.263% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 43.172% |
| Biotron Limited | -386.06 Thousand AUD | -2416.165% |
| Tissue Repair Ltd | -16.44 Million AUD | 40.916% |
| AdAlta Limited | -845.17 Thousand AUD | -1049.363% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 47.703% |
| Hexima Limited | -2.22 Million AUD | -336.351% |
| AnteoTech Limited | -5 Million AUD | -94.223% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 44.748% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -186.034% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -82.279% |
| Actinogen Medical Limited | -9.13 Million AUD | -6.378% |
| Immuron Limited | -11.48 Million AUD | 15.41% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 38.954% |